Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A OsterborgH Mellstedt

Abstract

CAMPATH-1H is a human immunoglobulin G1 (IgG1) anti-CD52 monoclonal antibody (MAb) that binds to nearly all B- and T-cell lymphomas and leukemias. We report the results of a multicenter phase II trial that used CAMPATH-1H in previously chemotherapy-treated patients with chronic lymphocytic leukemia (CLL). Twenty-nine patients who had relapsed after an initial response (n = 8) or were refractory (n = 21) to chemotherapy were treated with CAMPATH-1H administered as a 30-mg 2-hour intravenous (IV) infusion thrice weekly for a maximum period of 12 weeks. Eleven patients (38%) achieved a partial remission (PR) and one (4%) a complete remission (CR) (response rate, 42%; 95% confidence interval [CI], 23% to 61%). Three of eight patients (38%) with a relapse and nine of 21 refractory patients (43%) responded to CAMPATH-1H therapy. CLL cells were rapidly eliminated from blood in 28 of 29 patients (97%). CR in the bone marrow was obtained in 36% and splenomegaly resolved completely in 32%. Lymphadenopathy was normalized in only two patients (7%). The median response duration was 12 months (range, 6 to 25+). World Health Organization (WHO) grade IV neutropenia and thrombocytopenia developed in three (10%) and two patients (7%), respective...Continue Reading

Associated Clinical Trials

Citations

Jun 29, 1999·Nature Biotechnology·P S Chowdhury, I Pastan
Feb 13, 2001·British Journal of Haematology·J LundinA Osterborg
Nov 21, 2000·Current Opinion in Oncology·J M Flynn, J C Byrd
Feb 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Q NguyenE Whimbey
Apr 20, 2002·Current Opinion in Infectious Diseases·G Samonis, D P Kontoyiannis
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J KeatingP Hérait
Apr 20, 2002·Cancer Control : Journal of the Moffitt Cancer Center·John M BurkeDavid A Scheinberg
May 10, 2002·Leukemia & Lymphoma·Adam J BassDavid A Rizzieri
Aug 23, 2002·Current Opinion in Oncology·Karen E Kogel, Peter A McSweeney
Aug 1, 2002·Leukemia & Lymphoma·Steven L McCuneDavid A Rizzieri
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Blanche Mavromatis, Bruce D Cheson
Sep 3, 2003·European Journal of Haematology·G A KennedyH M Prince
Jun 7, 2003·Drugs·James E Frampton, Antona J Wagstaff
Oct 3, 2003·Leukemia·G Dighiero
Apr 17, 2004·British Journal of Haematology·D OscierUNKNOWN Guidelines Working Group of the UK CLL Forum. British Committee for Standards in Haematology
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul MoretonPeter Hillmen
Feb 5, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Tadeusz Robak
Jul 19, 2005·Cancer Immunology, Immunotherapy : CII·Farhad Ravandi, Susan O'Brien
Jul 2, 2005·Expert Opinion on Emerging Drugs·Kensei Tobinai
Aug 11, 2005·Current Oncology Reports·Nicole Lamanna
Oct 6, 2005·Blood·Emili MontserratFrancesc Bosch
Nov 25, 2006·Hematology·William G Wierda
Oct 6, 2006·Expert Review of Anticancer Therapy·Alessandra FerrajoliMichael J Keating
Oct 21, 2006·Cancer·Michael FieglUNKNOWN Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia
Jan 31, 2008·Leukemia & Lymphoma·David HuiLaurie Sehn
Nov 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph M Flynn, John C Byrd
Jul 8, 2008·Der Internist·G HeldM Pfreundschuh
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Winnie YeoPaul K S Chan
Apr 12, 2008·Expert Review of Anticancer Therapy·Kevin Boyd, Claire E Dearden
Apr 4, 2009·Targeted Oncology·Alfonso Quintás-Cardama, Susan O'Brien
Dec 29, 2009·Médecine sciences : M/S·Emilie RigalCyrille Hoarau
Apr 30, 2010·Cancer Control : Journal of the Moffitt Cancer Center·Javier Pinilla-Ibarz, Amy McQuary

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.